Oxford University Innovation Limited

Isis Innovation Limited

Alexander Douglas

Sarah C Gilbert

Matthew Guy Cottingham

Adrian V S Hill

Simon Draper

Matthew Dicks

Susan J Morris

Adrian Vivian Hill

Andrew Williams

Joseph Illingworth

Matthew Higgins

Katherine Wright

Adrian Vs Hill

The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector comprising the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orf1, E4Orf2 and E4Orf3 coding regions from AdY25.

Adenoviral vector

The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector comprising the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orfl, E4Orf2 and E4Orf3 coding regions from AdY25.

There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising fragments of Reticulocyte-binding protein Homologue 5 (PfRH5). In particular, the invention provides fragments of PfRH5 rationally designed on the basis of the PfRH5 crystal structure, wherein said fragments which lack disordered regions, particularly the flexible N-terminal region and/or flexible central linker.

Treatment and prevention of malaria

There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof.

Growing community of inventors

Oxford, United Kingdom

Alexander Douglas